J&J iBOT 3000
This article was originally published in The Gray Sheet
Executive Summary
National coverage determination will be sought for the stair-climbing wheelchair to enable payments beyond those provided by existing Medicare codes for power wheelchairs, according to the firm. The $29,000 device received PMA approval Aug. 13 (1"The Gray Sheet" Aug. 18, 2003, p. 3)...
You may also be interested in...
J&J’s iBOT Wins Expedited FDA Approval, Faces Reimbursement Roadblocks
FDA will evaluate the need for labeling revisions to Johnson & Johnson/Independence Technology's iBOT 3000 stair-climbing wheelchair upon receipt of four semi-annual reports from the company
Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time
Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.